Drug combo for advanced HER2-negative breast cancer
Part of Cancer clinical trials.
This study tests a new drug combination (QL1706 plus olaparib) for people with HER2-negative breast cancer that has progressed after earlier treatments. It aims to see if this combo can help shrink tumors or slow the cancer when the tumor has a specific DNA repair deficiency.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and are generally well enough to carry out light activity.
- You have HER2-negative breast cancer that has spread to other parts of the body (locally advanced or metastatic), and it is either hormone-receptor positive or triple-negative.
- You have already received 2 to 4 previous treatments for your advanced breast cancer.
- A test shows your tumor has a certain DNA repair problem (HRD) or you carry a BRCA gene mutation that likely causes cancer.
- You have at least one measurable tumor (a tumor that can be tracked with scans).
- Your bone marrow, kidney, liver, and blood clotting functions need to be within normal ranges, and your life expectancy is at least 12 weeks.
- If you could become pregnant, you must agree to use effective birth control and not breastfeed during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two antibody drugs (trastuzumab and pertuzumab) plus a targeted pill (olaparib) given before surgery to treat elderly women with HER2-positive breast cancer. The goal is to see if this approach helps shrink tumors or eliminate them entirely before surgery.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
This study tests a combination of two drugs — an immunotherapy (QL1706) and a PARP inhibitor (olaparib) — to see if it can help people with triple-negative breast cancer that has come back or spread, especially when their tumors have a specific DNA repair problem (HRD). It is for people who have already tried at least one prior treatment.
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
Hear when a new Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.